The trial aims to evaluate the the safety and tolerability of intravenous ME-143 in patients with refractory solid tumors.
The Phase I trial expects to recruit around 24 patients.
In pre-clinical studies, ME-143 has demonstrated potent activity against a number of tumor cell lines, including breast, colorectal and ovarian.